NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients

Authors:
  • SHS.A. Harrison
    S.A. Harrison
  • MAM.F. Abdelmalek
    M.F. Abdelmalek
  • JTJ.F. Trotter
    J.F. Trotter
  • APA.H. Paredes
    A.H. Paredes
  • HAH.L. Arnold
    H.L. Arnold
  • MKM. Kugelmas
    M. Kugelmas
  • MBM.R. Bashir
    M.R. Bashir
  • LLL. Ling
    L. Ling
  • SRS.J. Rossi
    S.J. Rossi
  • ADA.M. DePaoli
    A.M. DePaoli
  • MRM.E. Rinella
    M.E. Rinella
  • RLR.S. Loomba
    R.S. Loomba

Abstract
No abstract available